IP Library › Granted Patent US 12,391,739
Granted Patent B2
US 12,391,739 · App. 17/259,736 · Granted Aug 19, 2025

Method for producing gamma delta T cells

Inventors: Shin Kaneko (Kyoto, JP); Shoichi Iriguchi (Kyoto, JP); Tatsuki Ueda (Kyoto, JP); Yoshiaki Kassai (Kanagawa, JP); Akira Hayashi (Kanagawa, JP); Kazuhide Nakayama (Kanagawa, JP)
Assignees: Kyoto University; Takeda Pharmaceutical Company Limited
C07K14/7051A61K40/11A61K40/31A61K40/4211A61P35/00C07K14/5443C12N5/0636A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,739
App. No.
17/259,736
Granted
Aug 19, 2025
Kind
B2
Abstract

The present invention provides a method for producing a γδT cell from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an αβT cell.

Claims (20)

1. A method for producing a γδT cell from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an αβT cell, wherein the method comprises:

(1) establishing an induced pluripotent stem cell from a cell other than an αβT cell,

(2-1) differentiating the induced pluripotent stem cell established in (1) into a hematopoietic progenitor cell,

(2-2) differentiating the hematopoietic progenitor cell obtained from (2-1) into a T cell without using feeder cells, and

(3) introducing into any one of the (i) induced pluripotent stem cell obtained from step (1), (ii) a hematopoietic progenitor cell obtained from step (2-1) and (iii) a T cell obtained from step (2-2):

(a) a nucleic acid encoding a γTCR, and

(b) a nucleic acid encoding a δTCR.

2. The method according to claim 1 , wherein the cell other than an αβT cell is a mononuclear cell other than an αβT cell.

3. The method according claim 1 , wherein the cell other than an αβT cell is a monocyte.

4. The method according to claim 1 , the method further comprising a introducing into the (i) induced pluripotent stem cell obtained from step (1), (ii) a cell obtained during step (2-1) or step (2-2); and/or (iii) the induced pluripotent stem cell obtained from step (1) comprising the nucleic acid encoding a γTCR and the nucleic acid encoding the δTCR, or a cell obtained during step (2-1) or step (2-2) comprising the nucleic acid encoding a γTCR and the nucleic acid encoding the δTCR,

a nucleic acid encoding a CAR, which recognizes, and binds to a tumor-specific antigen or a tumor-associated antigen.

5. The method according to claim 1 , wherein the γTCR is Vγ9TCR and the δTCR is Vδ2TCR.

6. The method according to claim 1 , the method further comprising a introducing a nucleic acid encoding a fusion protein comprising IL-15 and IL-15Rα into the (i) induced pluripotent stem cell obtained from step (1), (ii) a cell obtained during step (2-1) or step (2-2); and/or (iii) the induced pluripotent stem cell obtained from step (1) comprising the nucleic acid encoding a γTCR and the nucleic acid encoding the δTCR, or the T cell obtained in step (2-1) or step (2-2) comprising the nucleic acid encoding the γTCR and the nucleic acid encoding the δTCR.

7. A γδT cell produced by the method according to claim 1 .

8. The method according to claim 1 , wherein the cell obtained during step (2-2) is an iPSC-derived T cell; or

wherein the cell obtained during step (2-1) is an iPSC-derived hematopoietic progenitor cell.

9. The method according to claim 4 , wherein the cell obtained during step (2-2) is an iPSC-derived T cell; or

wherein the cell obtained during step (2-1) is an iPSC-derived hematopoietic progenitor cell.

10. The method according to claim 6 , wherein the cell obtained during step (2-2) is an iPSC-derived T cell; or

wherein the cell obtained during step (2-1) is an iPSC-derived hematopoietic progenitor cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: KASSAI, YOSHIAKI; HAYASHI, AKIRA; NAKAYAMA, KAZUHIDE
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 054919/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: KANEKO, SHIN; IRIGUCHI, SHOICHI; UEDA, TATSUKI
To: KYOTO UNIVERSITY
Reel/Frame 054919/0507 →
Priority Claims (2)
JP 2018-133727 · Jul 13, 2018 · national
JP 2019-117891 · Jun 25, 2019 · national
Continuity (1)
Related Publication 20210130777A1 · May 6, 2021
References Cited (63)
US 9206394B2 · Nakauchi · 2015 [cited by examiner]
US 10660915B2 · Kaneko · 2020 [cited by examiner]
US 11401504B2 · Kawamoto · 2022 [cited by examiner]
US 11559548B2 · Kaneko · 2023 [cited by examiner]
US 11578310B2 · Kaneko · 2023 [cited by examiner]
US 11987811B2 · Kaneko · 2024 [cited by examiner]
US 20100009447A1 · Okamura et al. · 2010 [cited by applicant]
US 20120135525A1 · Rajesh · 2012 [cited by third party]
US 20170267972A1 · Kawamoto · 2017 [cited by third party]
US 20170326175A1 · Kaneko · 2017 [cited by third party]
US 20170333480A1 · Cooper · 2017 [cited by examiner]
US 20170369850A1 · Kaneko · 2017 [cited by examiner]
US 20190330596A1 · Kaneko et al. · 2019 [cited by applicant]
US 20200017837A1 · Aoi · 2020 [cited by applicant]
US 20210238550A1 · Yasui · 2021 [cited by examiner]
US 20220411752A1 · Kaneko · 2022 [cited by examiner]
US 20230000915A1 · Kaneko · 2023 [cited by examiner]
US 20230183645A1 · Kaneko · 2023 [cited by examiner]
US 20230357715A1 · Kawamoto · 2023 [cited by examiner]
US 20240052309A1 · Kaneko · 2024 [cited by examiner]
JP 2010017134A · 2010 [cited by applicant]
JP 2017535284A · 2017 [cited by applicant]
WO 2006006720A1 · 2006 [cited by applicant]
WO 2017041106A1 · 2014 [cited by applicant]
WO 2014165707A2 · 2014 [cited by applicant]
WO 2016073755A2 · 2016 [cited by applicant]
WO 2017075389A1 · 2017 [cited by applicant]
WO 2017221975A1 · 2017 [cited by applicant]
WO 2018135646A1 · 2018 [cited by applicant]
WO 2018143243A1 · 2018 [cited by applicant]
WO 2018147801A1 · 2018 [cited by applicant]
Watanabe et al., Development of IPSC-Based ydeltaT-Cell Immunotherapy for Digestive Cancer. Gastroenterology. Apr. 2017; 152(5 Suppl 1):S641, Abstract Su2054. (Year: 2017). [cited by examiner]
Van Acker, Heleen H et al. “Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.” Journal of hematology & oncology vol. 9,1 101. Sep. 29, 2016,… [cited by examiner]
Wu YL, Ding YP, Tanaka Y, Shen LW, Wei CH, Minato N, Zhang W. γδ T Cells and Their Potential for Immunotherapy. Int J Biol Sci 2014; 10(2):119-135. doi: 10.7150/ijbs.7823. https://www.ijbs.com/v10p0119.htm (Year: 2014). [cited by examiner]
Kawamoto, H., Masuda, K., Nagano, S et al. Cloning and expansion of antigen-specific T cells using iPS cell technology: development of “off-the-shelf” T cells for the use in allogeneic transfusion settings. Int J Hemato… [cited by examiner]
Reimann et al. Human T-Lymphoid Progenitors Generated in a Feeder-Cell-Free Delta-Like-4 Culture System Promote T-Cell Reconstitution in NOD/SCID/γc−/− Mice, Stem Cells, vol. 30, Issue 8, Aug. 2012, pp. 1771-1780 (Year:… [cited by examiner]
AOI, Cancer immunotherapy using allogenic iPS cell-derived ydetaIT cells. J Clin Exp Med;Dec. 23, 2017;263(11) 915-919. [cited by applicant]
Carpenter et al., Differentiating T-Cells from hiPSCs to Create Off-The-Shelf SPEAR T-Cell Therapies. Molecular Therapy. Apr. 2019;27(4S1):460, abstract 990. [cited by applicant]
Chang et al., Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells. PLoS One. May 14, 2014;9(5):e97335, 10 pages. [cited by applicant]
Smith et al., In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination. Stem Cells. Nov. 2015;33(11):3174-80. [cited by applicant]
Themeli et al., Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. Oct. 2013;31(10):928-33. [cited by applicant]
Watanabe et al., Development of IPSC-Based ydeltaT-Cell Immunotherapy for Digestive Cancer. Gastroenterology. Apr. 2017;152(5 Suppl 1):S641, Abstract Su2054. [cited by applicant]
Watanabe et al., Development of new gastrointestinal cancer treatment method using iPS cell-derived Vy9Vdelta2T Cell. Japan Digestive Disease Week, The Japanese Society of Gastroenterology. 2016, Abstract P-413. [cited by applicant]
Watanabe et al., The Generation of Human ydeltaT Cell-Derived Induced Pluripotent Stem Cells from Whole Peripheral Blood Mononuclear Cell Culture. Stem Cells Transl Med. Jan. 2018;7(1):34-44. [cited by applicant]
Zeng et al., Derivation of mimetic ydelta T cells endowed with cancer recognition receptors from reprogrammed ydelta T cell. PLoS One. May 9, 2019;14(5):e0216815, 20 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/JP2019/027697, dated Oct. 15, 2019, 30 pages. [cited by applicant]
European Office Action for Application No. 19833471.6, dated Jul. 4, 2022, 9 pages. [cited by applicant]
Stoklasek et al., Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. Nov. 1, 2006;177(9):6072-80. [cited by applicant]
Taiwan Search Report for Application No. 108124699, dated Aug. 3, 2023, 4 pages. [cited by applicant]
Mirzaei et al., Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. Oct. 1, 2016;380(2):413-423. [cited by applicant]
Singapore Office Action for Application No. 11202100260Q, dated Sep. 12, 2022, 9 pages. [cited by applicant]
Hurton et al., Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific cells. Proc Natl Acad Sci U S A. Nov. 29, 2016;113(48):E7788-E7797. [cited by applicant]
Leca et al., A monoclonal antibody to the Hodgkin's disease-associated antigen CD30 induces activation and long-term growth of human autoreactive gamma delta T cell clone. Cell Immunol. Jun. 1994;156(1):230-9. [cited by applicant]
Mediavilla-Varela et al., MPL-5821, an ESM-p38 MAPK inhibitor, enhances tumor immune response and M1 microphage polarization in a 3D Ex Vivo system utilizing fresh tumor microspheroids of lung cancer patients. Journal o… [cited by applicant]
Mzcardo et al., Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Rep. Mar. 20, 2018;22(12):3175-3190. [cited by applicant]
Yonezawa et al., SDF-1 has costimulatory effects on human T cells: possible involvement of MAPK (ERK2) activation. Microbiol Immunol. 2000;44(2):135-41. [cited by applicant]
Eurasian Search Report for Application No. 202490423, dated Nov. 20, 2024, 1 page. [cited by applicant]
Eurasian Search Report for Application No. 202490424, dated Nov. 19, 2024, 1 page. [cited by applicant]
Eurasian Search Report for Application No. 202490425, dated Nov. 21, 2024, 1 page. [cited by applicant]
Daisuke Watanabe et al. “The Generation of Human T Cell-Derived Induced Pluripotent Stem Cells from Whole Peripheral Blood Mononuclear Cell Culture” Stem Cells Translational Medicine; vol. 7(1), pp. 34-44; Jan. 2018. [cited by third party]
Mirelle J. A. J. Huijskens et al. “Technical Advance: Ascorbic Acid Induces Development of Double-Positive T Cells from Human Hematopoietic Stem Cells in the Absence of Stromal Cells” Journal of Leukocyte Biology; vol. … [cited by third party]
Atsutaka Minagawa et al. “Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy” Cell Stem Cell; vol. 23(6), pp. 850-872; Dec. 6, 2018. [cited by third party]
Nobuyuki Murai et al. “Re-Generation of Cytotoxic T Cells with Distinctive Signatures from Human T-Derived iPSCs” Stem Cell Reports, vol. 18(4), pp. 853-868; Apr. 11, 2023. [cited by third party]